1
|
Han S, Quach T, Hu L, Lim SF, Gracia G, Trevaskis NL, Simpson JS, Porter CJH. The Impact of Conjugation Position and Linker Chemistry on the Lymphatic Transport of a Series of Glyceride and Phospholipid Mimetic Prodrugs. J Pharm Sci 2020; 110:489-499. [PMID: 33069711 DOI: 10.1016/j.xphs.2020.10.021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2020] [Revised: 10/07/2020] [Accepted: 10/07/2020] [Indexed: 10/23/2022]
Abstract
Drug delivery to the lymphatic system is gaining increasing attention, particularly in fields such as immunotherapy where drug access to lymphocytes is central to activity. We have previously described a prodrug strategy that facilitates the lymphatic delivery of a model immunomodulator, mycophenolic acid (MPA) via incorporation into intestinal triglyceride transport pathways. The current study explored a series of structurally related glyceride and phospholipid mimetic prodrugs of MPA in an attempt to enhance lymph targeting and to better elucidate the design criteria for lipid mimetic prodrugs. MPA was conjugated to a glyceride or phospholipid backbone at various positions using different spacers employing ester, ether, carbonate and amide bonds. Patterns of prodrug hydrolysis were evaluated in rat digestive fluid, and lymphatic transport and plasma pharmacokinetics were assessed in lymph duct cannulated rats. Prodrugs with different spacers between MPA and the glyceride backbone resulted in up to 70-fold differences in gastrointestinal stability. MPA conjugation at the 2 position of the glyceride backbone and via an ester bond were most effective in promoting lymphatic transport. Phospholipid prodrug derivatives, or glyceride derivatives with MPA attached at the 1 position or when linked via ether, carbonate or amide bonds were poorly incorporated into lymphatic transport pathways.
Collapse
Affiliation(s)
- Sifei Han
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Tim Quach
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Luojuan Hu
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Shea Fern Lim
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Gracia Gracia
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Natalie L Trevaskis
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Jamie S Simpson
- Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia
| | - Christopher J H Porter
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria 3052, Australia.
| |
Collapse
|
2
|
Xia Y, Wu J, Wei W, Du Y, Wan T, Ma X, An W, Guo A, Miao C, Yue H, Li S, Cao X, Su Z, Ma G. Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination. NATURE MATERIALS 2018; 17:187-194. [PMID: 29300052 DOI: 10.1038/nmat5057] [Citation(s) in RCA: 163] [Impact Index Per Article: 27.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2016] [Accepted: 11/20/2017] [Indexed: 05/21/2023]
Abstract
A major challenge in vaccine formulations is the stimulation of both the humoral and cellular immune response for well-defined antigens with high efficacy and safety. Adjuvant research has focused on developing particulate carriers to model the sizes, shapes and compositions of microbes or diseased cells, but not antigen fluidity and pliability. Here, we develop Pickering emulsions-that is, particle-stabilized emulsions that retain the force-dependent deformability and lateral mobility of presented antigens while displaying high biosafety and antigen-loading capabilities. Compared with solid particles and conventional surfactant-stabilized emulsions, the optimized Pickering emulsions enhance the recruitment, antigen uptake and activation of antigen-presenting cells, potently stimulating both humoral and cellular adaptive responses, and thus increasing the survival of mice upon lethal challenge. The pliability and lateral mobility of antigen-loaded Pickering emulsions may provide a facile, effective, safe and broadly applicable strategy to enhance adaptive immunity against infections and diseases.
Collapse
Affiliation(s)
- Yufei Xia
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- University of Chinese Academy of Sciences, Beijing 100049, PR China
| | - Jie Wu
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- PLA Key Laboratory of Biopharmaceutical Production & Formulation Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Wei Wei
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Yiqun Du
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Tao Wan
- State Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, PR China
| | - Xiaowei Ma
- Hualan Biological Bacterin Co., Ltd, Xinxiang 453003, PR China
| | - Wenqi An
- Hualan Biological Bacterin Co., Ltd, Xinxiang 453003, PR China
| | - Aiying Guo
- Hualan Biological Bacterin Co., Ltd, Xinxiang 453003, PR China
| | - Chunyu Miao
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Hua Yue
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
| | - Shuoguo Li
- Center for Biological Imaging, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, PR China
| | - Xuetao Cao
- State Key Laboratory of Medical Immunology & Institute of Immunology, Second Military Medical University, Shanghai 200433, PR China
| | - Zhiguo Su
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- PLA Key Laboratory of Biopharmaceutical Production & Formulation Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- Jiangsu National Synergetic Innovation Center for Advanced Materials, Nanjing 211816, PR China
| | - Guanghui Ma
- State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- PLA Key Laboratory of Biopharmaceutical Production & Formulation Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, PR China
- Jiangsu National Synergetic Innovation Center for Advanced Materials, Nanjing 211816, PR China
| |
Collapse
|
3
|
Goud EV, Sivaramakrishna A, Vijayakrishna K. Aminophosphine Oxides: A Platform for Diversified Functions. Top Curr Chem (Cham) 2017; 375:10. [PMID: 28058632 DOI: 10.1007/s41061-016-0090-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2016] [Accepted: 11/23/2016] [Indexed: 10/20/2022]
Abstract
This review summarizes significant contributions reported on aminophosphine oxides (AmPOs), specifically those containing at least one amino group present as amino substituents on α- and β-carbons including direct P-N bond containing molecules. AmPOs have additional 'N' site(s), including highly basic 'P=O' groups, and these features make favor smooth and unexpected behavior. The most striking manifestations of flexibility of AmPOs are that they are exciting ligand systems for the coordination chemistry of actinides, and their involvement in catalytic organic reactions including enantioselective opening of meso-epoxides, addition of silyl enol ethers, allylation with allyltributylstannane, etc. The diverse properties of the AmPOs and their metal complexes demonstrate both the scope and complexity of these systems, depending on the basicity of phosphoryl group, and nature of the substituents on the pentavalent tetracoordinate phosphorus atom and metal. Two components key to understanding the challenges of actinide separations are detailed here, namely, previously described separation methods, and recent investigations into the fundamental coordination chemistry of actinides. Both are aimed at probing the critical features necessary for improved selectivity of separations. This review leads to the conclusion that, although many AmPOs have already been discovered and developed over the past century, many opportunities nevertheless exist for further developments towards new extraction processes and new catalytic materials by fine tuning the electronic and steric properties of substituents on the central phosphorus atom.
Collapse
Affiliation(s)
- E Veerashekhar Goud
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, 632 014, India
| | - Akella Sivaramakrishna
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, 632 014, India.
| | - Kari Vijayakrishna
- Department of Chemistry, School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, 632 014, India
| |
Collapse
|
4
|
Benito-Gallo P, Franceschetto A, Wong JC, Marlow M, Zann V, Scholes P, Gershkovich P. Chain length affects pancreatic lipase activity and the extent and pH–time profile of triglyceride lipolysis. Eur J Pharm Biopharm 2015; 93:353-62. [DOI: 10.1016/j.ejpb.2015.04.027] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Revised: 04/16/2015] [Accepted: 04/20/2015] [Indexed: 11/17/2022]
|
5
|
Giacalone G, Hillaireau H, Fattal E. Improving bioavailability and biodistribution of anti-HIV chemotherapy. Eur J Pharm Sci 2015; 75:40-53. [PMID: 25937367 DOI: 10.1016/j.ejps.2015.04.011] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Revised: 04/07/2015] [Accepted: 04/13/2015] [Indexed: 11/25/2022]
Abstract
In the context of the treatment of HIV/AIDS, many improvements have been achieved since the introduction of the combination therapy (HAART). Nevertheless, no cure for this disease has been so far possible, because of some particular features of the therapies. Among them, two important ones have been selected and will be the subject of this review. The first main concern in the treatments is the poor drug bioavailability, resulting in repeated administrations and therefore a demanding compliance (drug regimens consist of multiple drugs daily intake, and non-adherence to therapy is among the important reasons for treatment failure). A second important challenge is the need to target the drugs into the so-called reservoirs and sanctuaries, i.e. cells or body compartments where drugs cannot penetrate or are distributed in sub-active concentrations. The lack of antiviral action in these regions allows the virus to lie latent and start to replicate at any moment after therapy suspension. Recent drug delivery strategies addressing these two limitations will be presented in this review. In the first part, strategies to improve the bioavailability are proposed in order to overcome the absorption or the target cell barrier, or to extend the efficacy time of drugs. In the second section, the biodistribution issues are considered in order to target the drugs into the reservoirs and the sanctuaries, in particular the mononuclear phagocyte system and the brain.
Collapse
Affiliation(s)
- Giovanna Giacalone
- Institut Galien Paris-Sud, Université Paris-Sud, Faculté de Pharmacie, 5 rue J.-B. Clément, F-92290 Châtenay-Malabry, France; CNRS, UMR 8612, F-92290 Châtenay-Malabry, France.
| | - Hervé Hillaireau
- Institut Galien Paris-Sud, Université Paris-Sud, Faculté de Pharmacie, 5 rue J.-B. Clément, F-92290 Châtenay-Malabry, France; CNRS, UMR 8612, F-92290 Châtenay-Malabry, France.
| | - Elias Fattal
- Institut Galien Paris-Sud, Université Paris-Sud, Faculté de Pharmacie, 5 rue J.-B. Clément, F-92290 Châtenay-Malabry, France; CNRS, UMR 8612, F-92290 Châtenay-Malabry, France.
| |
Collapse
|
6
|
Han S, Hu L, Quach T, Simpson JS, Trevaskis NL, Porter CJH. Profiling the Role of Deacylation-Reacylation in the Lymphatic Transport of a Triglyceride-Mimetic Prodrug. Pharm Res 2014; 32:1830-44. [DOI: 10.1007/s11095-014-1579-9] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2014] [Accepted: 11/13/2014] [Indexed: 01/03/2023]
|
7
|
Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies. J Control Release 2014; 177:1-10. [PMID: 24398334 DOI: 10.1016/j.jconrel.2013.12.031] [Citation(s) in RCA: 71] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2013] [Revised: 12/22/2013] [Accepted: 12/27/2013] [Indexed: 11/20/2022]
Abstract
A lipophilic prodrug approach has been used to promote the delivery of a model immunomodulator, mycophenolic acid (MPA), to the lymphatic system after oral administration. Lymphatic transport was employed to facilitate enhanced drug uptake into lymphocytes, as recent studies demonstrate that targeted drug delivery to lymph resident lymphocytes may enhance immunomodulatory effects. Two classes of lymph-directing prodrugs were synthesised. Alkyl chain derivatives (octyl mycophenolate, MPA-C8E; octadecyl mycophenolate, MPA-C18E; and octadecyl mycophenolamide, MPA-C18AM), to promote passive partitioning into lipids in lymphatic transport pathways, and a triglyceride mimetic prodrug (1,3-dipalmitoyl-2-mycophenoloyl glycerol, 2-MPA-TG) to facilitate metabolic integration into triglyceride deacylation-reacylation pathways. Lymphatic transport, lymphocyte uptake and plasma pharmacokinetics were assessed in mesenteric lymph and carotid artery cannulated rats following intraduodenal infusion of lipid-based formulations containing MPA or MPA prodrugs. Patterns of prodrug hydrolysis in rat digestive fluid, and cellular re-esterification in vivo, were evaluated to examine the mechanisms responsible for lymphatic transport. Poor enzyme stability and low absorption appeared to limit lymphatic transport of the alkyl derivatives, although two of the three alkyl chain prodrugs - MPA-C18AM (6-fold) and MPA-C18E (13-fold) still increased lymphatic drug transport when compared to MPA. In contrast, 2-MPA-TG markedly increased lymphatic drug transport (80-fold) and drug concentrations in lymphocytes (103-fold), and this was achieved via biochemical incorporation into triglyceride deacylation-reacylation pathways. The prodrug was hydrolysed rapidly to 2-mycophenoloyl glycerol (2-MPA-MG) in the presence of rat digestive fluid, and 2-MPA-MG was subsequently re-esterified in the enterocyte with oleic acid (most likely originating from the co-administered formulation) prior to accessing the lymphatics and lymphocytes. Importantly, after administration of 2-MPA-TG, the concentrations of free MPA in the mesenteric lymph nodes were significantly enhanced (up to 28 fold) when compared to animals administered equimolar quantities of MPA, suggesting the efficient conversion of the esterified prodrug back to the pharmacologically active parent drug. The data suggest that triglyceride mimetic prodrugs have potential as a means of enhancing immunotherapy via drug targeting to lymphocytes and lymph nodes.
Collapse
|
8
|
Ravetti S, De Candia CA, Gualdesi MS, Pampuro S, Turk G, Quevedo MA, Briñón MC. Biological evaluation and molecular modelling of didanosine derivatives. MEDCHEMCOMM 2014. [DOI: 10.1039/c4md00003j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
These prodrugs of DDI with increased lipophilicity and good antiviral performance should be of interest in HIV therapy.
Collapse
Affiliation(s)
- Soledad Ravetti
- Departamento de Farmacia
- Facultad de Ciencias Químicas
- Ciudad Universitaria
- Universidad Nacional de Córdoba
- 5000 Córdoba, Argentina
| | - Cristian A. De Candia
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA
- INBIRS
- Facultad de Medicina
- Universidad de Buenos Aires
- Argentina
| | - María S. Gualdesi
- Departamento de Farmacia
- Facultad de Ciencias Químicas
- Ciudad Universitaria
- Universidad Nacional de Córdoba
- 5000 Córdoba, Argentina
| | - Sandra Pampuro
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA
- INBIRS
- Facultad de Medicina
- Universidad de Buenos Aires
- Argentina
| | - Gabriela Turk
- Instituto de Investigaciones Biomédicas en Retrovirus y SIDA
- INBIRS
- Facultad de Medicina
- Universidad de Buenos Aires
- Argentina
| | - Mario A. Quevedo
- Departamento de Farmacia
- Facultad de Ciencias Químicas
- Ciudad Universitaria
- Universidad Nacional de Córdoba
- 5000 Córdoba, Argentina
| | - Margarita C. Briñón
- Departamento de Farmacia
- Facultad de Ciencias Químicas
- Ciudad Universitaria
- Universidad Nacional de Córdoba
- 5000 Córdoba, Argentina
| |
Collapse
|
9
|
Arouri A, Hansen AH, Rasmussen TE, Mouritsen OG. Lipases, liposomes and lipid-prodrugs. Curr Opin Colloid Interface Sci 2013. [DOI: 10.1016/j.cocis.2013.06.001] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
10
|
Allain V, Bourgaux C, Couvreur P. Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices. Nucleic Acids Res 2011; 40:1891-903. [PMID: 22075995 PMCID: PMC3300006 DOI: 10.1093/nar/gkr681] [Citation(s) in RCA: 85] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
This short review aims at presenting some recent illustrative examples of spontaneous nucleolipids self-assembly. High-resolution structural investigations reveal the diversity and complexity of assemblies formed by these bioinspired amphiphiles, resulting from the interplay between aggregation of the lipid chains and base–base interactions. Nucleolipids supramolecular assemblies are promising soft drug delivery systems, particularly for nucleic acids. Regarding prodrugs, squalenoylation is an innovative concept for improving efficacy and delivery of nucleosidic drugs.
Collapse
Affiliation(s)
- Vanessa Allain
- Laboratoire de Physicochimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Université Paris-Sud 11, Faculté de Pharmacie, 5 rue J.B. Clément, 92296 Châtenay-Malabry, France
| | | | | |
Collapse
|
11
|
D’yakova LN, Shastina NS, Shvets VI. Lymphotropic prodrugs based on 2′,3′-didehydro-3′-deoxythymidine. Synthesis and sensitivity to hydrolysis. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY 2011. [DOI: 10.1134/s1070428011100241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
12
|
Skanji R, Andrieux K, Lalanne M, Caron J, Bourgaux C, Degrouard J, Brisset F, Gueutin C, Chacun H, Dereuddre-Bosquet N, Paci A, Vassal G, Bauduin L, Garcia-Argote S, Rousseau B, Clayette P, Desmaële D, Couvreur P. A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. Int J Pharm 2011; 414:285-97. [DOI: 10.1016/j.ijpharm.2011.05.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2011] [Revised: 04/27/2011] [Accepted: 05/02/2011] [Indexed: 10/18/2022]
|
13
|
Srinivas NR. The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges. Eur J Drug Metab Pharmacokinet 2011; 36:49-59. [PMID: 21404122 DOI: 10.1007/s13318-011-0035-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2011] [Accepted: 03/07/2011] [Indexed: 10/18/2022]
Abstract
The concept of prodrugs has been successfully executed for life cycle management options of several approved drugs and drugs in development. In addition to imparting ideal biopharmaceutical properties, such as solubility, permeability and lipophilicity, some prodrug concepts have also enabled site-specific drug delivery, prolonged the duration of therapeutic effect and improved therapeutic index. The strategic inclusion of prodrug concept during drug discovery and early development process brings in some unique challenges. The communication provides balanced perspectives on the rational use and challenges of prodrug concept during the drug discovery and development process.
Collapse
|